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BLOOD GLUCOSE MONITORING RECOMMENDATIONS AND
PRACTICES IN PATIENTS WITH TYPE 2 DIABETES: A SURVEY
OF HEALTH CARE PROFESSIONALS AND PATIENTS IN THE
UK
Yurgin NR1, Secnik K1, Cottrell S2, FitzGerald P2
1Eli Lilly and Company, Indianapolis, IN, USA, 2M-TAG Limited, a unit
of IMS, London, UK
OBJECTIVES: To survey healthcare professional (HCP) recom-
mendations and patient practices regarding blood glucose self-
monitoring among type-2 diabetic (T2D) patients receiving
pharmacotherapy and to investigate the potential impact of a
new incretin mimetic therapy (IMT). METHODS: HCPs in the
UK (N = 50) were interviewed using structured questionnaire
methodology. The survey investigated recommended and actual
frequencies of self-monitoring according to type of therapy (oral
therapy alone [oral(s)], insulin ± oral therapy) and phase of treat-
ment (initiation, steady state), and investigated self-monitoring
recommendations for the IMT. Additionally, patients with T2D
(N = 26) were questioned by structured telephone interview.
RESULTS: The average frequency of self-monitoring recom-
mended by HCPs was 3–4 times higher for patients on insulin ±
oral than for those on oral(s) (p < 0.001). Regarding actual self-
monitoring frequencies at steady state, 50% of HCPs believed
patients on insulin ± oral tested less than recommended. Fewer
HCPs (39%) believed that patients on oral(s) self-monitored less
than recommended (p ≤ 0.05). In contrast, most patients (~70%)
believed themselves compliant, regardless of therapy type. Most
HCPs (~98%) would recommend that patients on the IMT self-
monitor less than or the same as if they were on insulin ± oral,
with the majority indicating that patients on IMT monitor less
frequently. In comparison, most HCPs (>84%) would recom-
mend that patients on IMT self–monitor the same as or more
than if they were on oral(s), with the majority indicating that
patients on IMT monitor the same as oral(s) only at steady state.
CONCLUSIONS: HCPs recommend signiﬁcantly more frequent
self-monitoring for patients on insulin ± oral than oral(s). 
HCPs perceive patients on oral(s) to be more compliant to 
self-monitoring than those on insulin ± oral. Overall, patients 
see themselves as more compliant than do HCPs. The HCP 
recommended frequency for self-monitoring with the new 
IMT would lie between the recommended frequencies for 
oral(s) and insulin ± oral, but more similar to oral(s) at steady
state.
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ANTIDIABETIC MEDI CATION PRESCRIBING TRENDS IN
FRANCE: EVIDENCE FROM PRIMARY CARE PHYSICIANS
Secnik K1,Yurgin NR1, Lage MJ2
1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthMetrics
Outcomes Research, Groton, CT, USA
OBJECTIVE: Objectives were to examine prescribing patterns
of antidiabetic medications in France over time and to determine
how patient characteristics impact the likelihood of receiving
various medications. METHODS: Data were obtained from the
IMS Disease Analyzer-Mediplus France Database. Patients were
eligible if they were identiﬁed as having Type 2 diabetes during
the calendar year 2001, 2002 or 2003. Univariate analyses exam-
ined changes in patient characteristics and trends in prescribing
over time. In addition, multivariate logistic regressions were used
to analyze how prescribing patterns have changed over time.
RESULTS: A total of 14,281 unique diabetic patients were exam-
ined over the time period from 2001 to 2003. A unique drug
therapy episode was deﬁned as any use of medication or med-
ication combination for at least 45 days. Among users of antidi-
abetic agents, individuals had an average of 1.28 drug therapy
episodes per calendar year. Univariate analyses revealed that
between 2001 and 2003, monotherapy use of sulfonylurea
decreased (p < 0.0001), while monotherapy use of metformin (p
< 0.0001) and insulin (p = 0.0437) increased. Multivariate logis-
tic regressions that compared prescription therapy episodes in
2003 to those in 2001 revealed that the inﬂuence of year on like-
lihood of using metformin or insulin (either alone or in combi-
nation with other medications) was positive and signiﬁcant (p <
0.05). In contrast, the inﬂuence of year on the likelihood of using
sulfonylurea monotherapy was negative and signiﬁcant (p <
0.05). CONCLUSIONS: Antidiabetic medication prescribing
patterns have changed in France in the early 21st century. In
general, the trend has been away from sulfonylurea monother-
apy and towards metformin and insulin monotherapy or com-
bination therapy.
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RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL
STUDY WITH PROPENSITY SCORE METHODS: CAN THEIR
RESULTS CONVERGE?—A CASE STUDY IN ESTIMATING
MARGINAL EFFECT OF INSULIN REGIMENS ON THE
REDUCTION OF HEMOGLOBIN A1C AMONG PATIENTS WITH
TYPE 2 DIABETES
Sun P, Liu C, Xu R
Lilly Research Laboratories, Indianapolis, IN, USA
Randomized controlled trials (RCT) and observational studies
with propensity score methods (PSM) are the two common
approaches to mimic counterfactual premises in estimating treat-
ment effects. Although, in theory, correct exercises of either
approach can reveal the similar truth, no empirical evidence has
shown such convergence. OBJECTIVE: To examine whether
similar studies using either approach can reach converging
results of a treatment effect. METHODS: Two small 32-week
crossover RCTs (n = 105 and 97; crossover at 16th weeks) and
one large retrospective observational study with PSM (n = 4519)
were conducted to examine and compare the marginal effect of
insulin regimen (once-daily basal analog insulin—glargine vs.
twice-daily basal and bolus analog insulin—lispro mix 75/25) on
the reduction of hemoglobin A1c (HbA1c) among patients with
type 2 diabetes. The differences in mean HbA1c reductions
between two insulin regimens were estimated as the marginal
effect for individual studies. RESULTS: Two RCTs showed that
twice-daily basal and bolus analog insulin (lispro 75/25) had 0.4
and 0.6 more units of HbA1c reduction than once-daily basal
analog insulin (glargine) respectively. Likewise, the retrospective
observational study with PSM also found that twice-daily basal
and bolus analog insulin (lispro 75/25) reduced 0.55 and 0.65
more units of HbA1c than once-daily basal analog insulin
(glargine) at the end of 1st and 2nd post-baseline quarters respec-
tively. CONCLUSIONS: Two RCTs and 1 observational study
with PSM revealed that twice-daily short-acting analog insulin
regimen (lispro 75/25) reduced more unit of HbA1c than once-
daily long-acting analog insulin regimen (glargine) did. This fact
supports that correct exercises of RCTs and observational studies
with PSM can reveal the similar level of treatment effect.
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EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL
EQUATIONS (UKPDS 68),AND THE UKPDS RISK ENGINE
EQUATIONS (UKPDS 56 AND 60) IN FORECASTING
CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2
DIABETES
McEwan P1, Bergenheim K2, Currie CJ1
1Cardiff University, Cardiff, UK, 2AstraZeneca, Mölndal, Sweden
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OBJECTIVES: Updated risk equations are available for predict-
ing outcome in people with type 2 diabetes (T2D): the UKPDS
Outcomes Model (UKPDS 68). It is important to assess the valid-
ity of applying risk equations to populations other than those
from which they were derived. The objective was to evaluate
how well the UKPDS-68 equations predicted vascular morbidity
and mortality in real-life data from Cardiff, UK, and compare
estimates with the previous UKPDS Risk Engine equations
(UKPDS-RE [from UKPDS publications 56 and 60]).
METHODS: The equations were incorporated into a stochastic
simulation model that estimated the incidence and prevalence of
complications (DiabForecaster). Predicted results from the model
were compared with population data from Cardiff for coronary
heart disease (CHD), stroke and all cause mortality. The annual
incidence of newly diagnosed T2D, baseline modiﬁable risk
factors and demographic proﬁles were matched to the Cardiff
data. RESULTS: Internal validation, using a baseline cohort
matched to the UKPDS study, demonstrated that the model pre-
dicted 12-year cumulative incidence in line with previous UKPDS
publications. Real life and predicted event rates for CHD were:
116, 153 and 137 events/1000 T2D patients/yr for the Cardiff
data, UKPDS-RE and UKPDS-68, respectively. For stroke: 178,
153 and 128 events/1000 T2D patients/yr, respectively. For all
cause mortality: 418, 430, and 475 events/1000 T2D patients/yr,
respectively. CONCLUSIONS: All UKPDS equations demon-
strated internal validity when compared with published UKPDS
data, however both UKPDS-RE and UKPDS-68 equations over
predicted the incidence of CHD and mortality and under pre-
dicted stroke. While all endpoints predicted were reasonably
concordant with observational data discrepancies between
UKPDS-68 and UKPDS-RE are worthy of further investigation.
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EFFECTS OF INDUCING CORRELATION AMONG
CHOLESTEROL PARAMETERS ON OUTCOMES IN
SIMULATION OF PHARMACEUTICAL EFFECTIVENESS
Frick KD1, Sorensen SV2, Hollenbeak C3,Wade A2
1Johns Hopkins University, Baltimore, MD, USA; 2United BioSource
Corporation, Center for Health Economics and Policy, Bethesda, MD,
USA; 3Surgery and Health Evaluation Sciences, Penn State College of
Medicine, Hershey, PA, USA and Visiting Scientist, United BioSource
Corporation, Center for Health Economics & Policy, Bethesda, MD,
USA
OBJECTIVES: To determine whether inducing correlation
among triglyceride, HDL, and LDL levels in a pharmaceutical
treatment Monte Carlo simulation affects parameters’ means
and variances; proportion with all parameters controlled; and
summary statistics of estimated total cholesterol. METHODS:
Means, standard deviations, and correlations among the choles-
terol parameters were estimated from NHANES data for meta-
bolic syndrome (MS) and diabetic patients with all parameters
uncontrolled. For simulation, distributions were ﬁt to the data.
Analyses used 1000 replications of populations of 1000. Popu-
lations were generated without correlated parameters and with
correlation induced in the uncorrelated data. Estimated changes
with fenoﬁbrate, statins, and a combination were taken from the
literature. Total cholesterol was approximated using HDL, plus
LDL, plus 20% of triglycerides. Differences in means and ratios
of variances comparing uncorrelated and correlated results were
calculated for each replication. Null hypotheses were rejected
when the interval the middle 95% of replications spanned did
not include zero for differences and one for ratios. RESULTS:
Correlations were higher for diabetic than MS patients. Despite
the data’s and distribution’s non-normality, induced correlations
were close to NHANES correlations. Correlation did not affect
the summary statistics of individual parameters or the propor-
tion with all parameters under control. Correlation affected
results for total cholesterol, the sum of other parameters. For
MS, variance of total cholesterol was less than 7% lower with
uncorrelated data than with correlated data. For diabetic
patients, variance of total cholesterol was more than 20% higher
with uncorrelated data. Findings held for subpopulations with
and without all parameters controlled after taking medication.
Variance results were similar across treatments. Total cholesterol
means differed primarily for MS subgroups. CONCLUSIONS:
Summary statistics (particularly variance) for sums of parame-
ters are affected by correlation in Monte Carlo simulations.
Underestimated and overestimated variances increase the risk of
Type I and II error respectively.
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MARGINAL STRUCTURAL MODELS—AN EXPLANATION AND
ILLUSTRATION
Gause D, Plauschinat C, Kahler K
Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: 1) Provide a concise explanation of “inverse
probability of treatment weights” (IPTWs) for estimating mar-
ginal structural models (MSM), pointing out its advantages and
disadvantages to alternative methods of adjusting for covariates
in observational studies, and 2) illustrate use of MSM for com-
paring impact of drug use on medical costs. METHODS: Con-
founding can be controlled by stratiﬁcation or with covariates in
regression. When there are many confounders adjustment using
propensity scores is sometimes used but these are 1) not easily
generalized with more than two comparison groups, and 2) may
result in residual confounding when matching is used, and is not
helpful with time dependent covariates affected by the exposures
being compared. An alternative is based on modeling the “mar-
ginal” distribution of counterfactuals associated with each group
(as described by Robins, Hernan, and Brumback [2000]). This
is accomplished using weights related to propensity scores. A
MSM will be illustrated by comparing outpatient medical costs
for patients taking diabetic drug treatments, adjusting for both
baseline and subsequent time dependent diagnoses and lab data.
A multinomial logit model is used to estimate each subject’s con-
ditional probability of receiving TZD, sulfonylurea, or met-
formin given their history of baseline and time dependent
covariates. RESULTS: These predicted probabilities are basis for
IPTWs used to estimate mean marginal outpatient costs for each
drug group. CONCLUSIONS: Effects of confounders are broken
when their associations with drug treatment groups are broken,
and this can be done using MSM where the data is reweighted
such that confounders have similar distributions within drug
comparison groups.
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ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT
DIABETES—A METHODOLOGICAL COMPARISON USING A
CLAIMS DATABASE
Yang M1, Barner JC1, Rascati KL1, Lawson KA1,Wilson JP1,
Crismon ML1,Worchel J2, Mascarenas C3
1University of Texas at Austin, Austin,TX, USA, 2Central Texas
Veterans Health Care System, Austin,TX, USA, 3South Texas Veterans
Health Care System, San Antonio,TX, USA
OBJECTIVE: To evaluate the robustness of the relationship
between antipsychotic utilization and treatment-emergent dia-
betes among patients newly initiated on therapy, when method-
ologies were varied while controlling for covariates.
METHODS: Seven models were created based on the following
methodological variations: 1) study designs (retrospective cohort
and case-control); 2) treatment exposure assignment (intent-to-
treat (ITT) and as-treated (AT)); and 3) statistical approaches
